drugset
drugset / Trial / NCT02631252

Phase I Study of Mitoxantrone and Etoposide Combined With Hydroxychloroquine, for Relapsed Acute Myelogenous Leukemia

NCT02631252 ↗

Phase 1 Terminated 1 enrolled Alison Sehgal, MD, MS
NaSingle-groupOpen-labelTreatment

Summary

This is an open label phase I clinical trial of hydroxychloroquine (HCQ) ,when it is combined with the usual medications for acute myeloid leukemia, mitoxantrone and etoposide. The purpose of this study is to find the safest and most effective dose of hydroxychloroquine with these medications. The investigators will be testing to see if it can increase the effectiveness of mitoxantrone and etoposide.

Timeline

Start
2016-08-18
Primary completion
2016-09-17
Completion
2017-10-02

Drugs

EvaluationDrugModalityDoseRoute
Subject Hydroxychloroquine Small molecule 600 mg Oral
Subject Hydroxychloroquine Small molecule 1400 mg Oral
Background Etoposide Small molecule 100 mg/m2 Intravenous
Background Mitoxantrone Small molecule 10 mg/m2 Intravenous

Indications

acute myeloid leukemia